These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 28679965)
1. Plasmablastic lymphoma with unfavorable chromosomal abnormalities related to plasma cell myeloma: A borderline case between plasmablastic lymphoma and plasmablastic plasma cell myeloma. Aoyama Y; Tsunemine H; Kodaka T; Oda N; Matsuoka H; Itoh T; Takahashi T J Clin Exp Hematop; 2017; 57(1):37-39. PubMed ID: 28679965 [No Abstract] [Full Text] [Related]
2. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Taddesse-Heath L; Meloni-Ehrig A; Scheerle J; Kelly JC; Jaffe ES Mod Pathol; 2010 Jul; 23(7):991-9. PubMed ID: 20348882 [TBL] [Abstract][Full Text] [Related]
3. Lymphoid Neoplasms With Plasmablastic Differentiation: A Comprehensive Review and Diagnostic Approaches. Chen BJ; Chuang SS Adv Anat Pathol; 2020 Mar; 27(2):61-74. PubMed ID: 31725418 [TBL] [Abstract][Full Text] [Related]
4. Plasmablastic lymphoma versus anaplastic myeloma in a human immunodeficiency virus negative male: a diagnostic quandary. Jain BB; Majumdar A; Chowdhary KM Arch Iran Med; 2013 Oct; 16(10):608-10. PubMed ID: 24093145 [TBL] [Abstract][Full Text] [Related]
5. Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma. Chen BJ; Yuan CT; Yang CF; Ho CH; Lin YK; Su YZ; Chou HC; Chuang SS Virchows Arch; 2022 Aug; 481(2):283-293. PubMed ID: 35657404 [TBL] [Abstract][Full Text] [Related]
6. CD31 expression in plasmacytic/plasmablastic lesions. Plocharczyk E; Wakely PE Ann Diagn Pathol; 2013 Dec; 17(6):498-501. PubMed ID: 24074836 [TBL] [Abstract][Full Text] [Related]
7. [Plasmablastic myeloma initially presented with ascites]. Sato S; Tsunoda S; Kamata W; Tamai Y Rinsho Ketsueki; 2022; 63(3):194-200. PubMed ID: 35387932 [TBL] [Abstract][Full Text] [Related]
8. Cutaneous localization of plasmablastic multiple myeloma with heterotopic expression of CD3 and CD4: Skin involvement revealing systemic disease. Varricchio S; Pagliuca F; Travaglino A; Gallo L; Villa MR; Mascolo M J Cutan Pathol; 2019 Aug; 46(8):619-622. PubMed ID: 31025408 [TBL] [Abstract][Full Text] [Related]
9. [Plasmablastic lymphoma presenting clinical symptoms similar to plasmablastic myeloma]. Nakaya A; Nagate Y; Toda J; Yamashita Y; Hirose Y; Mori K; Shibayama H Rinsho Ketsueki; 2023; 64(4):260-264. PubMed ID: 37121769 [TBL] [Abstract][Full Text] [Related]
10. Plasmablastic haemato-lymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib. Dasanu CA; Bauer F; Codreanu I; Padmanabhan P; Rampurwala M Hematol Oncol; 2013 Sep; 31(3):164-6. PubMed ID: 22899491 [TBL] [Abstract][Full Text] [Related]
11. Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort. Møller HE; Preiss BS; Pedersen P; Kristensen IB; Hansen CT; Frederiksen M; Abildgaard N; Møller MB APMIS; 2015 Aug; 123(8):652-8. PubMed ID: 26152595 [TBL] [Abstract][Full Text] [Related]
12. Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma. Ahn JS; Okal R; Vos JA; Smolkin M; Kanate AS; Rosado FG J Clin Pathol; 2017 Sep; 70(9):775-780. PubMed ID: 28249941 [TBL] [Abstract][Full Text] [Related]
13. High-grade plasmablastic neoplasm of humerus in an HIV-negative patient, which was indeterminate between plasmablastic lymphoma and plasmablastic myeloma. Mondal SK; Bera H; Biswas PK; Mallick MG J Cancer Res Ther; 2011; 7(2):214-6. PubMed ID: 21768719 [TBL] [Abstract][Full Text] [Related]
14. Bone marrow infiltration by plasmablastic neoplasm: plasmablastic myeloma or plasmablastic lymphoma? Eladl E; Chang H Blood; 2021 Mar; 137(9):1268. PubMed ID: 33661296 [No Abstract] [Full Text] [Related]
15. Treatment strategy in a patient showing borderline features between plasmablastic lymphoma and plasmablastic myeloma harboring a 17p deletion. Yoshihara K; Yoshihara S; Matsuda I; Imado T; Matsuo S; Okada M; Shimizu Y; Hirota S; Fujimori Y Ann Hematol; 2020 Jun; 99(6):1405-1407. PubMed ID: 32125468 [No Abstract] [Full Text] [Related]
16. Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge. Montes-Moreno S; Montalbán C; Piris MA Leuk Lymphoma; 2012 Feb; 53(2):185-94. PubMed ID: 21812534 [TBL] [Abstract][Full Text] [Related]
17. [Characteristics and Prognostic Significance of Cytogenetic Abnormalities in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement]. Liu W; Lyu R; Huang WY; Li CW; Liu H; Li J; Zou DH; Qiu LG; Yi SH Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):761-765. PubMed ID: 28641631 [TBL] [Abstract][Full Text] [Related]
18. Peroxiredoxin I is differentially expressed in multiple myelomas and in plasmablastic lymphomas. Demasi AP; Magalhães MH; Furuse C; Araújo NS; Junqueira JL; Araújo VC Oral Dis; 2008 Nov; 14(8):741-6. PubMed ID: 18565146 [TBL] [Abstract][Full Text] [Related]
19. Plasmablastic transformation of plasma cell myeloma with heterotropic expression of CD3 and CD4: a case report. Mishra P; Kakri S; Gujral S Acta Clin Belg; 2017 Aug; 72(4):250-253. PubMed ID: 27374484 [TBL] [Abstract][Full Text] [Related]
20. Genetic Basis of Extramedullary Plasmablastic Transformation of Multiple Myeloma. Liu Y; Jelloul F; Zhang Y; Bhavsar T; Ho C; Rao M; Lewis NE; Cimera R; Baik J; Sigler A; Sen F; Yabe M; Roshal M; Landgren O; Dogan A; Xiao W Am J Surg Pathol; 2020 Jun; 44(6):838-848. PubMed ID: 32118627 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]